Boston Scientific reports above-consensus Q4 results, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Boston Scientific (BSX) PT Raised to $120 at Jefferies
February 5, 2025 2:48 PM ESTJefferies analyst Matthew Taylor raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $100.00) while maintaining a Buy rating.
The analyst comments "BSX reported 4Q24 sales of $4.56B, +19.5% organic, vs cons $4.42B and EPS of $0.70 +27% vs cons $0.66. BSX introduced '25 guidance... More
Boston Scientific (BSX) PT Raised to $122 at Citi
February 5, 2025 2:06 PM ESTCiti analyst Joanna Wuensch raised the price target on Boston Scientific (NYSE: BSX) to $122.00 (from $107.00) while maintaining a Buy rating.
The analyst commment "BSX delivered another strong quarter meaningfully surpassing consensus, with four of the eight segments delivering double-digit growth, including Electrophysiology sales... More
Boston Scientific (BSX) PT Raised to $120 at BTIG
February 5, 2025 2:00 PM ESTBTIG analyst Marie Thibault raised the price target on Boston Scientific (NYSE: BSX) to $120.00 (from $101.00) while maintaining a Buy rating.
The analyst comments "High-flying BSX reported another strong quarter, posting Q4 revenue of $4.561B (+22.4% rep., +19.5% org.) and adj. EPS of $0.70 (consensus: $4.416B and $0.66), well above its guidance of 14-16% organic sales growth and $0.64-$0.66 adj. EPS. The beat was once again led by Electrophysiology which grew ~172% y/y to $649M (consensus $575M), driven by Farapulse, which surpassed $1B in global revenue in 2024. Watchman grew 20% y/y org. to $413M, above consensus of $406M,... More
